Skip to main content

Advertisement

SpringerLink
Log in

High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Previously, we reported that the accuracy of cytological diagnosis of breast lesions could be augmented through the quantitative assessment of DNA methylation of fine-needle aspirate (FNA) washings. Herein, we aimed at the evaluation of the prognostic value of quantitative promoter methylation at three gene loci (APC, CCND2, and RASSF1A) in a large series of FNA washings from breast lesions. Methylation levels of three gene promoters were assessed by quantitative methylation-specific PCR in bisulfite-modified DNA from 211 FNA washings, comprising 178 carcinomas and 33 benign lesions, both histopathologically confirmed. Receiver operator characteristic (ROC) curve analysis was used to determine the diagnostic performance of the gene panel in distinguishing cancer from non-cancerous lesions. Relevant clinicopathologic data and time to progression and/or death from breast cancer were correlated with methylation findings. Log-rank test and Cox-regression model identified independent predictors of prognosis. APC, CCND2, and RASSF1A methylation levels differed significantly between malignant and benign lesions. ROC curve analysis confirmed the diagnostic performance of the gene panel. In univariate analysis, stage was significantly associated with overall, disease-specific and disease-free survival, whereas tumor grade was associated with disease-specific and disease-free survival. Remarkably, RASSF1A methylation was significantly and independently associated with worse disease-free survival in the final multivariate analysis. We confirmed that quantitative gene promoter methylation augments the diagnostic performance of cytopathology. Importantly, and in addition to standard clinicopathologic parameters, RASSF1A high-methylation levels are independent predictors of worse outcome in breast cancer. Thus, epigenetic biomarkers provide valuable tools for breast cancer patient management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781

    Article  PubMed  CAS  Google Scholar 

  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249

    Article  PubMed  Google Scholar 

  3. Jeronimo C, Costa I, Martins MC, Monteiro P, Lisboa S, Palmeira C et al (2003) Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res 9(9):3413–3417

    PubMed  CAS  Google Scholar 

  4. Nemec CF, Listinsky J, Rim A (2007) How should we screen for breast cancer? Mammography, ultrasonography, MRI. Clevel Clin J Med 74(12):897–904

    Article  Google Scholar 

  5. Hamill J, Campbell ID, Mayall F, Bartlett AS, Darlington A (2002) Improved breast cytology results with near patient FNA diagnosis. Acta Cytol 46(1):19–24

    Article  PubMed  Google Scholar 

  6. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358(11):1148–1159

    Article  PubMed  CAS  Google Scholar 

  7. Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8(4):286–298

    Article  PubMed  CAS  Google Scholar 

  8. Hinshelwood RA, Clark SJ (2008) Breast cancer epigenetics: normal human mammary epithelial cells as a model system. J Mol Med 86(12):1315–1328

    Article  PubMed  Google Scholar 

  9. Liu JW, Nagpal JK, Jeronimo C, Lee JE, Henrique R, Kim MS et al (2008) Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer. Prostate 68(4):418–426

    Article  PubMed  CAS  Google Scholar 

  10. Lo PK, Sukumar S (2008) Epigenomics and breast cancer. Pharmacogenomics 9(12):1879–1902

    Article  PubMed  CAS  Google Scholar 

  11. Page DL, Sakamoto G (1987) Infiltrating carcinoma: major histological types. Churchill-Livingstone, Edinburgh

    Google Scholar 

  12. Elston CW, Ellis IO (1998) Assessment of histological grade. Churchill Livingstone, Edinburgh

    Google Scholar 

  13. Greene FLPD, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer, New York

    Book  Google Scholar 

  14. Clark SJ, Harrison J, Paul CL, Frommer M (1994) High sensitivity mapping of methylated cytosines. Nucleic Acids Res 22(15):2990–2997

    Article  PubMed  CAS  Google Scholar 

  15. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D et al (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28(8):E32

    Article  PubMed  CAS  Google Scholar 

  16. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H (2002) Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 160(2):605–612

    Article  PubMed  CAS  Google Scholar 

  17. Jeronimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D et al (2004) Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res 10(12 Pt 1):4010–4014

    Article  PubMed  CAS  Google Scholar 

  18. Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL et al (2007) High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 13(20):6122–6129

    Article  PubMed  CAS  Google Scholar 

  19. Pu RT, Laitala LE, Alli PM, Fackler MJ, Sukumar S, Clark DP (2003) Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod Pathol 16(11):1095–1101

    Article  PubMed  Google Scholar 

  20. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P (2004) Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 10(18 Pt 1):6189–6193

    Article  PubMed  CAS  Google Scholar 

  21. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21(10):1973–1979

    Article  PubMed  CAS  Google Scholar 

  22. Euhus DM, Bu D, Milchgrub S, Xie XJ, Bian A, Leitch AM et al (2008) DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev 17(5):1051–1059

    Article  PubMed  CAS  Google Scholar 

  23. Van der Auwera I, Bovie C, Svensson C, Trinh XB, Limame R, van Dam P et al (2010) Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer 10:97

    Article  PubMed  Google Scholar 

  24. Jin Z, Tamura G, Tsuchiya T, Sakata K, Kashiwaba M, Osakabe M et al (2001) Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer 85(1):69–73

    Article  PubMed  CAS  Google Scholar 

  25. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E et al (2003) DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 63(22):7641–7645

    PubMed  Google Scholar 

  26. Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE et al (2006) Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 24(26):4262–4269

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

V.L.C is supported by a grant from Fundação para a Ciência e a Tecnologia (SFRH/BD/23374/2005). This study was funded by grants from Liga Portuguesa contra o Cancro—Núcleo Regional do Norte and the Comissão de Fomento da Investigação em Cuidados de Saúde—Ministério da Saúde (Project no. 21/2007).

Author information

Authors and Affiliations

  1. Cancer Epigenetics Group, Research Center of the Portuguese Oncology Institute, Porto, Portugal

    Ana Teresa Martins, João Ramalho-Carvalho, Vera L. Costa, Rui Henrique & Carmen Jerónimo

  2. Department of Pathology, Portuguese Oncology Institute, Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal

    Ana Teresa Martins, Paula Monteiro, Conceição Leal & Rui Henrique

  3. Department of Genetics, Portuguese Oncology Institute, Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal

    João Ramalho-Carvalho, Vera L. Costa & Carmen Jerónimo

  4. Department of Gastroenterology, Portuguese Oncology Institute, Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal

    Mário Dinis-Ribeiro

  5. Department of Biostatistics and Medical Informatics, Faculty of Medicine, University of Porto, Porto, Portugal

    Mário Dinis-Ribeiro

  6. Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal

    Rui Henrique & Carmen Jerónimo

Authors
  1. Ana Teresa Martins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paula Monteiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. João Ramalho-Carvalho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vera L. Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mário Dinis-Ribeiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Conceição Leal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rui Henrique
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carmen Jerónimo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carmen Jerónimo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martins, A.T., Monteiro, P., Ramalho-Carvalho, J. et al. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. Breast Cancer Res Treat 129, 1–9 (2011). https://doi.org/10.1007/s10549-010-1160-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-1160-0

Keywords

Search

Navigation